{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:14:28Z","timestamp":1755926068303,"version":"3.37.3"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research"],"published-print":{"date-parts":[[2017,4,17]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), was under development for the treatment of cardiovascular (CV) disease. The purpose of this pre\u2010postnatal study in rabbits was to evaluate the effects of evacetrapib on pregnancy, parturition, and lactation of the maternal animals and on the growth, viability, development, and reproductive performance of the first filial (F1) offspring. The rabbit is considered a relevant species for toxicity testing with evacetrapib as it demonstrates significant CETP expression, whereas mice and rats do not express significant levels of CETP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Evacetrapib was administered daily by oral gavage from gestation day (GD) 7 through lactation day (LD) 41 at dose levels of 0, 10, 30, and 100 mg\/kg\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no adverse effects on maternal survival, clinical signs, gestation length, parturition, and litter size. There were no effects on F1 clinical observations, body weight, sexual maturation, conditioned eye blink, functional observational battery, or pathology findings. Treatment\u2010related decreases in F1 postnatal survival and equivocal reductions in F1 mating, fertility, and copulation\/conception indices without changes in sperm parameters or pathology of reproductive organs were noted in F1 animals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The maternal no observed adverse effect level (NOAEL) after evacetrapib administration in female rabbits was 100 mg\/kg\/day. Based on the decreased F1 postnatal survival and equivocal changes in F1 fertility, the NOAEL for F1 neonatal developmental was 30 mg\/kg\/day. Birth Defects Research 109:486\u2013496, 2017.\u00a9 2017 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bdr2.1017","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T10:28:14Z","timestamp":1490956094000},"page":"486-496","source":"Crossref","is-referenced-by-count":1,"title":["Prenatal and Postnatal Assessment in Rabbits with Evacetrapib: A Cholesteryl Ester Transfer Protein Inhibitor"],"prefix":"10.1002","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-9693","authenticated-orcid":false,"given":"William J.","family":"Breslin","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories Lilly Corporate Center Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim G.","family":"Hilbish","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Lilly Corporate Center Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen A.","family":"Cannady","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Lilly Corporate Center Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy L.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Charles River Laboratories Ashland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"579","article-title":"Collaborative Behavioral Teratology Study: protocol design and testing procedures","volume":"7","author":"Adams J","year":"1985","journal-title":"Neurobehav Toxicol Teratol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1022"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M018069"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200073024"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_2_6_8_1","unstructured":"Crestor.2016.Full prescribing information Crestor (rosuvastatin). Reference ID 3937746. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021366s033lbl.pdf."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1964.10490181"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2307\/2528490"},{"key":"e_1_2_6_11_1","first-page":"197","volume-title":"Twenty years of classical conditioning with the rabbit. Progress in Psychobiology and Physiological Phychology. Vol 10","author":"Gormezano I","year":"1983"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-0491(98)10038-X"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-4959(03)00046-0"},{"key":"e_1_2_6_14_1","first-page":"468","volume-title":"Nonparametric Statistical Methods","author":"Hollander M","year":"1999"},{"key":"e_1_2_6_15_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.2005.ICH Harmonised Tripartite Guideline. Detection of toxicity to reproduction for medicinal products and toxicity to male fertility S5(R2). Available at:http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S5\/Step4\/S5_R2__Guideline.pdf."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod17.2.298"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1952.10483441"},{"key":"e_1_2_6_18_1","unstructured":"Lipitor.2015.Full prescribing information Lipitor (atorvastatin). Reference ID 3714589. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020702s065lbl.pdf."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00663-3"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)38413-3"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1649"},{"key":"e_1_2_6_22_1","unstructured":"Praluent.2015.Full prescribing information Praluent (alirocumab). Reference ID 3797282. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125559Orig1s000lbledt.pdf."},{"key":"e_1_2_6_23_1","unstructured":"Repatha.2015.Full prescribing information Repatha (evolocumab). Reference ID 3812424. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125522s000lbl.pdf."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.032662099"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415575153"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.962"},{"key":"e_1_2_6_27_1","first-page":"215","volume-title":"Statistical Methods","author":"Snedecor GW","year":"1980"},{"key":"e_1_2_6_28_1","first-page":"504","volume-title":"Principles and Procedures of Statistics: A Biometrical Approach","author":"Steel RGD","year":"1980"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/tcm.1770040203"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000151"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12287"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.24.579"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.8.6.737"},{"key":"e_1_2_6_34_1","unstructured":"Zetia.2012.Full prescribing information Zetia (ezetimibe). Reference ID 3076051. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021445s033lbl.pdf."}],"container-title":["Birth Defects Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdr2.1017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdr2.1017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:56:16Z","timestamp":1696618576000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdr2.1017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,4,17]]}},"alternative-id":["10.1002\/bdr2.1017"],"URL":"https:\/\/doi.org\/10.1002\/bdr2.1017","archive":["Portico"],"relation":{},"ISSN":["2472-1727","2472-1727"],"issn-type":[{"type":"print","value":"2472-1727"},{"type":"electronic","value":"2472-1727"}],"subject":[],"published":{"date-parts":[[2017,3,31]]}}}